Research work · 2019

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Ann Burtness, Kevin Joseph Harrington, Richard Greil

The Lancet

Download PDF

DOI: 10.1016/s0140-6736(19)32591-7